# US 2026/0092310 A1 · Cas12a compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092310 A1
- Document ID: US20260092310A1
- Status: Published application
- Kind: A1
- Application number: 19/341,788
- Filed: 2025-09-26
- Published: 2026-04-02
- Earliest claimed: 2024-09-27
- Assignees: New England Biolabs, Inc.
- Applicants: New England Biolabs, Inc.
- Inventors: Juan Pan; G. Brett Robb; Nathan Tanner; Ivan R. Correa, JR.
- Web page: https://patentgrep.com/patent/US20260092310A1

## CPC

- C12Q 1/6823: Release of bound markers
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/34: involving hydrolase
- C12Q 1/485: {involving kinase}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6844: Nucleic acid amplification reactions
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- G01N 2333/9126: DNA-directed DNA polymerase (2.7.7.7)
- G01N 2333/922: Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
- G01N 2333/924: acting on glycosyl compounds (3.2)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates, in some embodiments to compositions comprising a variant Cas12a and one-pot methods of using a variant Cas12a with amplification to detect a sequence of interest.

## Claims

### Claim 1

A composition comprising:
a variant Cas12a having an amino acid sequence at least 90% identical to one or more of SEQ ID NOS: 1-16, wherein the variant Cas12a has thermostable cis recognition activity and thermostable trans nuclease activity;
a crRNA operable with the variant Cas12a; and
optionally, a non-naturally occurring buffer.

### Claim 2 (depends on 1)

A composition according to claim 1 further comprising a trans nuclease substrate.

### Claim 3 (depends on 1)

A composition according to claim 1, wherein the trans nuclease substrate comprises a fluorophore, a linker polynucleotide, and a quencher, wherein the fluorophore and the quencher are each operably linked to the linker polynucleotide and wherein the quencher is operable to quench the fluorophore.

### Claim 4 (depends on 3)

A composition according to claim 3, wherein the linker polynucleotide is disposed between the fluorophore and quencher and is susceptible to trans nuclease cleavage.

### Claim 5 (depends on 1)

A composition according to claim 1, wherein the molar ratio of variant Cas12a: crRNA is 1:1 to 1:20.

### Claim 6 (depends on 1)

A composition according to claim 1, wherein the amino acid sequence is at least 95% identical to one or more of SEQ ID NOS: 1-16.

### Claim 7 (depends on 1)

A composition according to claim 1, wherein the composition is cell-free.

### Claim 8 (depends on 1)

A composition according to claim 1, wherein the composition has a dried, freeze dried, lyophilized, crystalline, or aqueous form.

### Claim 9 (depends on 1)

A composition according to claim 1, wherein the variant Cas12a is immobilized on a support with or without a linker.

### Claim 10 (depends on 1)

A composition according to claim 1 further comprising a DNA polymerase, a glycosylase, a nicking enzyme, a ligase, a helicase, a recombinase, a crowding agent, a DNA binding protein, a dye, an additive, a ribonucleoprotein, and/or combinations thereof.

### Claim 11 (depends on 1)

A composition according to claim 1 further comprising a Bst DNA polymerase, Bsu DNA polymerase, phi29 DNA polymerase, phi29-XT DNA polymerase, and/or variants thereof.

### Claim 12 (depends on 1)

A composition according to claim 1 further comprising a uracil DNA glycosylase.

### Claim 13

A one-pot method comprising contacting at a single temperature and in a single container:
a variant Cas12a having an amino acid sequence at least 90% identical to one or more of SEQ ID NOS: 1-16, wherein the variant Cas12a has thermostable cis recognition activity and thermostable trans nuclease activity;
a crRNA operable with the variant Cas12a, wherein the molar ratio of variant Cas12a:
crRNA is optionally 1:1 to 1:20;
a polynucleotide comprising a nucleic acid sequence of interest;
amplification primers complementary to at least a portion of the sequence of interest and operable to support amplification of the sequence of interest;
optionally, a reverse transcriptase;
a DNA polymerase;
a trans nuclease substrate; and
optionally, a non-naturally occurring buffer.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the variant Cas12a and the crRNA are contacted in a single container under conditions that permit loop mediated amplification of the sequence of interest and trans nuclease cleavage of the trans nuclease substrate to produce a detectable trans nuclease cleavage marker.

### Claim 15 (depends on 13)

A method according to claim 13, wherein the method is performed at a single temperature in a range of 50-70° C., 55-65° C., or 50-60° C.

### Claim 16 (depends on 13)

A method according to claim 13, wherein the amplification primers and the polynucleotide comprising the nucleic acid sequence of interest hybridize to form an amplification substrate for the DNA polymerase.

### Claim 17 (depends on 14)

A method according to claim 14 further comprising amplifying, by the DNA polymerase, the amplification substrate to produce an amplification product.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the amplifying is selected from genome exponential amplification reaction (GEAR), helicase-dependent amplification (HDA), loop-mediated isothermal amplification (LAMP), multiple displacement amplification (MDA), nicking enzyme amplification reaction (NEAR), nucleic acid sequence-based amplification (NASBA), ramification (RAM), recombinase polymerase amplification (RPA), rolling circle amplification (RCA), self-sustained sequence replication (3SR), single primer isothermal amplification (SPIA), strand displacement amplification (SDA), transcription mediated amplification (TMA), or combinations thereof.

### Claim 19 (depends on 17)

A method according to claim 17, wherein the crRNA hybridizes to the polynucleotide comprising the nucleic acid sequence of interest, the amplification product, or combinations thereof to form a cleavage assembly comprising the crRNA, the polynucleotide, and the variant Cas12a.

### Claim 20 (depends on 19)

A method according to claim 19, wherein the variant Cas12a cleaves the polynucleotide comprising the nucleic acid sequence of interest.

### Claim 21 (depends on 20)

A method according to claim 20, wherein the variant Cas12a cleaves the trans nuclease substrate to form a trans nuclease cleavage product.

### Claim 22 (depends on 21)

A method according to claim 21 further comprising detecting the trans nuclease cleavage product.

### Claim 23 (depends on 22)

A method according to claim 22, wherein detecting the trans nuclease cleavage product comprises optically detecting the trans nuclease cleavage product and/or electrochemically detecting the trans nuclease cleavage product.

### Claim 24 (depends on 13)

A method according to claim 13, wherein the molar ratio of variant Cas12a: crRNA is 1:1 to 1:20.

### Claim 25

A variant Cas12a having an amino acid sequence at least 90% identical to one or more of SEQ ID NOS: 1-16, wherein the variant Cas12a has thermostable cis recognition activity and thermostable trans nuclease activity.
